Data-augmented machine learning redefines the effective concentration of eculizumab in complement blood disorders

Lucía Alfonso-González[1,2], Francisco J. Fernández[1,2*#], Manuel Praga[3], Kaare Mikkelsen[4], M. Cristina Vega[1*#]

[1]Centro de Investigaciones Biológicas Margarita Salas (CIB-CSIC), Consejo Superior de Investigaciones Científicas, 28040 Madrid, Spain.

[2]Abvance Biotech SL, Pharmacokinetics, Pharmacodynamics & Drug Metabolism (PPDM), 28003 Madrid, Spain.

[3]Department of Medicine, Complutense University, 28040 Madrid, Spain.

[4]Aarhus University, Department of Electrical and Computer Engineering, 8000 Aarhus, Denmark.

* Correspondence:
Francisco J. Fernández
fjfernandez@abvance.com
M. Cristina Vega
cvega@cib.csic.es

[#]Equally contributing senior authors

Running title: ML redefines eculizumab effective concentration

Abstract

Eculizumab, a humanized monoclonal antibody targeting the complement lytic

pathway protein C5, has demonstrated high efficacy in the treatment of

paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome,

generalized myasthenia gravis, and neuromyelitis optica spectrum disorder.

However, recent reports have highlighted patients who exhibit a lack of treatment

response, necessitating an increase in the recommended dose or a reduction in

the dosing interval. In this study, we employed machine-learning predictive

models to identify the optimal blood concentration of eculizumab to inhibit the

complement lytic pathway. Additionally, we examined the impact of data

augmentation through the generation of artificial data on the predictive

performance of these models. In conclusion, our machine learning model

predicts that the target blood concentration of eculizumab should be increased

to a minimum of 152-162 µg mL–1 (up from 50-100 µg mL–1) to achieve a more

complete inhibition of the complement system's lytic pathway.

Eculizumab (Soliris®) is a humanized monoclonal antibody that binds complement

protein C5, blocking its cleavage and preventing activation of the lytic pathway of the

complement system[1]. The drug has regulatory approval from both the US FDA and the

EMA for the treatment of the rare complement-mediated disorders paroxysmal

nocturnal hemoglobinuria (PNH; ORPHA: 67038), atypical hemolytic uremic syndrome

(aHUS; ORPHA: 213653), generalized myasthenia gravis (gMG; ORPHA: 512), and

neuromyelitis optica spectrum disorder (NMOSD; ORPHA: 71291)[2]. Across these

indications, eculizumab has demonstrated efficacy in reducing disease activity and

improving patient outcomes[2]. The most prominent safety concern is the increased

susceptibility to invasive infection by *Neisseria meningitidis*, necessitating vaccination

and ongoing vigilance[3]. Additional long-term adverse effects, such as hepatotoxicity,

are increasingly reported and warrant systematic evaluation[4,5].

The optimal serum concentration of eculizumab required for sustained inhibition of the

complement lytic pathway remains uncertain. The widely cited therapeutic range of 50-

100 µg/ml is not derived from robust pharmacokinetic-pharmacodynamic studies and

has therefore been questioned[1,6]. In clinical practice, both under- and overexposure

have been observed. Subtherapeutic trough levels are associated with reduced

efficacy and recurrence of disease manifestations[7], whereas the clinical consequences

of overexposure are less well defined[8]. Nonetheless, cases of drug accumulation and

excessively high trough levels, particularly in children, have been documented[8,9]. This

uncertainty is compounded by the extraordinary cost of therapy, estimated at US

$700,000 per patient annually. These factors underscore the need for precise

strategies to determine effective dosing, minimizing the risk of underdosing while

avoiding unnecessary overexposure.

Advances in data-driven technologies are transforming healthcare by enabling machine

learning (ML) models that improve diagnostic accuracy, reduce costs, and support

personalized treatment strategies. Yet these benefits are often limited by access to

large and diverse datasets, especially in rare diseases, where clinical evidence is

inherently sparse. Synthetic data generation provides a solution: artificially created

datasets that reproduce the statistical properties of real patient data while expanding

sample size and diversity. Used responsibly, synthetic augmentation can enhance

model robustness and reduce bias while safeguarding patient privacy. This approach is

particularly important for complement-mediated rare disorders, where the scarcity of

trial participants and the heterogeneity of disease symptoms make traditional data

collection inadequate for reliable pharmacological modeling.

We have reassessed the serum concentration of eculizumab needed to inhibit

complement activation in rare hematological disorders. Using publicly available clinical

data from small multicenter studies across four rare indications (**Supplementary Table**

S1), we trained supervised ML models to predict the likelihood of complete C5

inhibition based on drug concentration. Acknowledging the data scarcity inherent in

rare diseases, we employed synthetic data augmentation to improve model robustness

and generalizability. Our study adheres to the TRIPOD-AI checklist (**Supplementary**

Table S2).

Clinical data on serum levels of eculizumab (total drug) and free (unbound) C5 from

PNH, aHUS, gMG, and NMOSD were used as inputs (390 independent observations)

for training, validation and testing of various supervised ML classification algorithms

(**Fig. 1a**). Observations were labelled as Inhibition = True when free C5 concentrations

were ≤0.5 µg/ml, and Inhibition = False when >0.5 µg/ml. This threshold has been

previously validated as an indicator of complete complement inhibition[13]. To estimate

the concentration of eculizumab required for sustained inhibition, classifiers were

queried with input values ranging from 10 to 1700 µg/ml, and the lowest concentration

yielding ≥80% predicted probability of inhibition was recorded. Classifier performance

was evaluated using standard metrics of predictive accuracy (**Table 1**). Among the

models tested, K-Nearest Neighbors (KNN) achieved the highest overall performance,

with an average accuracy of 0.90 and an ROC AUC of 0.89.

The predictive ability of ML models depends on data quantity and quality. To address

the limitations of sample size, we created synthetic data using multiple methods and

assessed the augmented datasets for both statistical accuracy and downstream

predictive performance (**Fig. 1b-f**). Synthetic data generated with MOSTLY AI most

closely matched real distributions and was chosen for further analyses (**Fig. 1g**).

Combining real and synthetic datasets improved classifier accuracy across all

algorithms (**Supplementary Table S3**). To examine the impact of synthetic

augmentation alone, we also trained models only on synthetic data and tested them on

real data (**Fig. 1g**). As the dataset size grew, the prediction of the Inhibited class

improved, reaching an accuracy and ROC AUC of 0.91 and 0.92, respectively, at $N =$

10,000.

Using this augmented framework, the best-performing classifiers predicted that

complete complement blockade is achieved with serum eculizumab concentrations

above 162 µg/ml (KNN) or 152 µg/ml (Random Forest) (**Supplementary Table S3**). To

provide a robust and transparent estimate, we applied a consensus modeling strategy

consistent with OECD QSAR validation principles and FDA/EMA recommendations for

model-informed drug development. We therefore report a consensus threshold of 157

µg/ml, with an inter-model range of 152-162 µg/ml, as the effective maintenance

concentration required for reliable C5 inhibition. Since dosing regimens for rare

diseases are sensitive to miscalibration, data-augmented ML-based predictions should

help mitigate the risk of clinical underdosing in current eculizumab maintenance

regimens.

Our findings align with previous reports indicating higher thresholds than the commonly

cited 50-100 µg/ml. For example, Reiss et al.[14] linked concentrations above 124 µg/ml

with complete blockade, while Latour et al.[15] observed no hemolysis episodes in

patients above 150 µg/ml. Clinical trial data in aHUS (and gMG) also report mean

serum concentrations above 116-150 µg/ml during effective treatment[16]. Substantial

inter-patient variability further complicates dosing. Cases of aHUS patients and up to

16% of PNH patients have been reported with subtherapeutic trough levels under

standard regimens[15,17–19], whereas others exhibit concentrations >500 µg/ml despite

guideline-based dosing[8,20,21]. This variability underscores the importance of monitoring

trough levels and adjusting both dose and interval to avoid treatment failure or

overexposure. Together, these results support revising the traditional target range

upwards to ensure consistent therapeutic efficacy.

Limitations of our study stem from the inherent "small-n" barrier that characterizes rare

diseases and constrains the robustness of meta-analyses. Methodologically, using

supervised ML introduces the risk of overfitting, which can be through cross-validation

and consensus modeling. Synthetic data augmentation, while deliberately applied to

overcome sample scarcity, also introduces assumptions: artificially generated datasets

may not fully represent the biological and clinical variability of real patients, especially

in underrepresented groups. Our analysis focused on serum eculizumab and free C5

concentrations as primary predictors; other potentially relevant biomarkers (e.g.,

sC5b9, or patient-specific genetic factors) were not included and could impact the true

dose-response relationship. Moreover, the available data and the design of this model

do not allow extrapolation of the target concentration achieved with a given dosing

regimen. These limitations emphasize the need for prospective validation with larger,

more diverse patient populations, ideally incorporating mechanistic complement

models, such as C-model, and real-world pharmacokinetic and pharmacodynamic data,

which may further enhance interpretability and clinical applicability.

ML approaches, combined with carefully validated synthetic data, offer a powerful way

to fill knowledge gaps in rare-disease treatments. In this context, simulated data are

crucial for training ML on rare diseases due to the limited availability of clinical data,

while also protecting patients' privacy. By expanding small training datasets while

maintaining their statistical structure, this strategy allows for more accurate, clinically

relevant predictions and supports model-based drug development in situations where

traditional data collection is difficult. Additionally, this approach provides a scalable

template for improving other therapeutics with limited trial data.

Acknowledgments

MCV acknowledges the CSIC Network of Rare Diseases (RER-CSIC). LAG

acknowledges support from the PhD program in Medicinal Chemistry at the

Universidad Complutense de Madrid (UCM) (Spain) and a research visiting fellowship

at Aarhus University (Denmark).

Funding

This work was funded by the Spanish Ministerio de Ciencia e Innovación-Recovery,

Transformation and Resilience Plan (PRTR) grants PDC2022-133713-I00 (MCV) and

CPP2022-009838 (FJF and MCV); grant S2022/BMD-7278 from the Regional

Government of Madrid (MCV); the European Commission – NextGenerationEU through

CSIC's Global Health Platform ("PTI Salud Global") (SGL2103020) (MCV); and the

Instituto de Salud Carlos III (ISCIII) grant PI24/00925 (MCV). It was also supported by

the Research Network on Complement in Health and Disease (RED2022-134750-T)

(MCV). LAG received support through an Industrial PhD grant (IND2019/BMD-17219)

from the Regional Government of Madrid (FJF and MCV).

Authorship

MCV and FJF conceived and designed the study. LAG, FJF, and MCV drafted and

revised the work for intellectual content and context. KM analyzed the machine learning

algorithms and data. MP contributed to the study's conception and design and revised

the manuscript to ensure the clinical relevance of the results. All authors contributed

critically to the manuscript. MCV and FJF obtained the resources, administered, and

supervised the project, and are responsible for the published work.

Conflict-of-interest

Abvance Biotech SL provided salaries for LAG and FJF. The remaining authors declare

no competing financial interests.

Disclosures

The authors declare no further conflicts of interest.

Data availability

All data analyzed in this study are included in this article and its supplementary

information files.

Code availability

The custom code developed for this study may be shared with qualified researchers

upon reasonable request to the corresponding author.

References

1. Wijnsma KL, ter Heine R, Moes DJAR, et al. Pharmacology, Pharmacokinetics and
Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach
to Eculizumab. *Clin Pharmacokinet*. 2019;58(7):859-874. doi:10.1007/s40262-019-
00742-8

2. Alexion Pharmaceuticals. SOLIRIS- eculizumab injection, solution, concentrate.
2022. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ebcd67fa-b4d1-
4a22-b33d-ee8bf6b9c722

3. Alashkar F, Vance C, Herich-Terhürne D, Preising N, Dührsen U, Röth A. Serologic
response to meningococcal vaccination in patients with paroxysmal nocturnal
hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor
eculizumab. *Ann Hematol*. 2017;96(4):589-596. doi:10.1007/s00277-017-2924-y

4. Hayes W, Tschumi S, Ling SC, Feber J, Kirschfink M, Licht C. Eculizumab
hepatotoxicity in pediatric aHUS. *Pediatr Nephrol*. 2015;30(5):775-781.
doi:10.1007/s00467-014-2990-5

5. Oruc A, Ayar Y, Vuruskan BA, et al. Hepatotoxicity associated with eculizumab in a
patient with atypical hemolytic uremic syndrome. *Nefrologia (Engl Ed)*.
2018;38(4):448-450. doi:10.1016/j.nefro.2017.10.001

6. European Medicines Agency (EMA). *Soliris: EPAR-Product Information.*; 2023.
https://www.ema.europa.eu/en/medicines/human/EPAR/soliris

7. Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the
complement inhibitor eculizumab for the treatment of patients with paroxysmal
nocturnal hemoglobinuria. *Blood*. 2008;111(4):1840-1847. doi:10.1182/blood-2007-
06-094136

8. Wehling C, Amon O, Bommer M, et al. Monitoring of complement activation
biomarkers and eculizumab in complement-mediated renal disorders. *Clin Exp
Immunol*. 2017;187(2):304-315. doi:10.1111/cei.12890

9. Cullinan N, Gorman KM, Riordan M, Waldron M, Goodship THJ, Awan A. Case
Report: Benefits and Challenges of Long-term Eculizumab in Atypical Hemolytic
Uremic Syndrome. *Pediatrics*. 2015;135(6):e1506.

10. Lysaght T, Lim HY, Xafis V, Ngiam KY. AI-Assisted Decision-making in Healthcare.
ABR. 2019;11(3):299-314. doi:10.1007/s41649-019-00096-0

11. Alsentzer E, Li MM, Kobren SN, Noori A, Kohane IS, Zitnik M. Few shot learning for
phenotype-driven diagnosis of patients with rare genetic diseases. *npj Digit Med*.
2025;8(1):380. doi:10.1038/s41746-025-01749-1

12. Jordon J, Szpruch L, Houssiau F, et al. *Synthetic Data -- What, Why and How?* The
Royal Society; 2022.

13. Monteleone JPR, Gao X, Kleijn HJ, Bellanti F, Pelto R. Eculizumab
Pharmacokinetics and Pharmacodynamics in Patients With Generalized
Myasthenia Gravis. *Front Neurol.* 2021;12. doi:10.3389/fneur.2021.696385

14. Reiss UM, Schwartz J, Sakamoto KM, Puthenveetil G, Ogawa M, Ware RE.
Efficacy and Safety of Eculizumab in Children and Adolescents with Paroxysmal
Nocturnal Hemoglobinuria. *Blood.* 2011;118(21):1034.
doi:10.1182/blood.V118.21.1034.1034

15. Peffault de Latour R, Fremeaux-Bacchi V, Porcher R, et al. Assessing complement
blockade in patients with paroxysmal nocturnal hemoglobinuria receiving
eculizumab. *Blood.* 2015;125(5):775-783. doi:10.1182/blood-2014-03-560540

16. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in
atypical hemolytic-uremic syndrome. *N Engl J Med.* 2013;368(23):2169-2181.
doi:10.1056/NEJMoa1208981

17. Thomson N, Ulrickson M. Maintenance eculizumab dose adjustment in the
treatment of atypical hemolytic uremic syndrome: a case report and review of the
literature. *Clin Case Rep.* 2016;4(8):773-776. doi:10.1002/ccr3.628

18. Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in
paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.
Blood. 2011;117(25):6786-6792. doi:10.1182/blood-2011-02-333997

19. DeZern AE, Dorr D, Brodsky RA. Predictors of hemoglobin response to eculizumab
therapy in paroxysmal nocturnal hemoglobinuria. *Eur J Haematol.* 2013;90(1):16-
24. doi:10.1111/ejh.12021

20. Greenbaum LA, Fila M, Ardissino G, et al. Eculizumab is a safe and effective
treatment in pediatric patients with atypical hemolytic uremic syndrome. *Kidney Int.*
2016;89(3):701-711. doi:10.1016/j.kint.2015.11.026

21. Volokhina E, Wijnsma K, Molen R, et al. Eculizumab Dosing Regimen in Atypical
HUS: Possibilities for Individualized Treatment. *Clin Pharmacol Ther.*
2017;102:671-678. doi:10.1002/cpt.686

22. Amiri H, Kohane IS, Undiagnosed Diseases Network. Machine Learning of Patient
Characteristics to Predict Admission Outcomes in the Undiagnosed Diseases
Network. *JAMA Netw Open.* 2021;4(2):e2036220.
doi:10.1001/jamanetworkopen.2020.36220

23. Lucía AG, M. Cristina V, Francisco J. F. C-model: A comprehensive enhanced
pharmacokinetic/pharmacodynamic simulation environment targeting the
complement system. *British journal of pharmacology.* 2025;182(13):2842-2860.
doi:10.1111/bph.70054

24. Volokhina E, Wijnsma K, Molen R, et al. Eculizumab Dosing Regimen in Atypical
HUS: Possibilities for Individualized Treatment. *Clin Pharmacol Ther.*
2017;102:671-678. doi:10.1002/cpt.686

Tables

Table 1. Comparison of the performance of machine learning models trained and

tested on real data. Results are provided considering 10-fold cross-validation.

ML model	Complement inhibition = F			Complement inhibition = T		
	Precision	**Recall**	**F1 sc.**	**Precision**	**Recall**	**F1 sc.**
K-Nearest Neighbors	**0.95**	0.93	**0.94**	0.77	**0.83**	**0.80**
Extreme Gradient Boosting	0.94	0.92	0.93	0.74	0.80	0.77
Logistic regression	0.94	0.91	0.92	0.71	0.78	0.75
Gradient Boosting	0.93	0.91	0.92	0.72	0.76	0.74
Random Forest	0.93	0.91	0.92	0.71	0.75	0.73
Support Vector Machines	0.88	0.93	0.91	0.70	0.57	0.63
Gaussian Naïve Bayes	0.85	**0.97**	0.90	**0.79**	0.39	0.52

Figure Legends

Figure 1. Predictive model of eculizumab maintenance concentration and evaluation of classifier performance with and without synthetic data. (a) Data on blood concentration of eculizumab and free (unbound) C5 (fC5). (b-e) Evaluation of MOSTLY-AI synthetic dataset based on its similarity to real data using statistical techniques: (b) feature correlation, (c) absolute logarithmic mean and standard deviation of numeric data, (d) first components of Principal Component Analysis, and (e) distribution per feature. Analysis made using the TableEvaluator Python library (version 1.5.0). (f) Evaluation of the MOSTLY-AI dataset compared to real data as a function of data utility. The MOSTLY-AI-generated dataset (blue) was compared with the synthetic dataset generated using other techniques (gray) and the real dataset (black), based on the F1-score of classifiers constructed using the same algorithms - Logistic Regression (LR), Random Forest (RF), Gaussian Naïve Bayes (GNB), K-Nearest Neighbors (KNN), Support Vector Machine (SVM), Gradient Boosting (GB) and Extreme Gradient Boosting (XGBoost). (g) Model performance evolution in real and synthetic data combinations. Evolution of the F1-score of models trained and tested on synthetic data in combination with real data (blue); and trained on synthetic data and tested on real data (coral), in comparison with the F1-score obtained in models trained and tested on real data (black).

 Figures

284   **Figure 1. Predictive model of eculizumab maintenance concentration and**
285   **evaluation of classifier performance with and without synthetic data**.